Peptide Half-Life Explained: What the Biological Clock Measures
Understand what a measured half-life describes, how remaining fractions are calculated, and why biological exposure and a prepared vial’s shelf life are different questions.
| Basic meaning | Time for a measured quantity to fall by half in a defined phase |
|---|---|
| Simple decay model | Each half-life halves the remaining amount |
| Key dependency | Analyte, model, route, sampling, and analysis |
| Important distinction | Biological half-life is not solution shelf life |
| Interpretation limit | Persistence does not establish duration of every effect |
| Hero product | Hero SM |
Peptide half-life describes a measured decline over time. The useful question is which quantity declined, in which system, and during which part of its time course. A number without those details can look precise while answering the wrong question.
Biological half-life also differs from the shelf life of a research solution. One concerns behavior in a biological or experimental system. The other concerns whether a stored preparation retains specified quality attributes. This guide explains the distinction and the arithmetic behind a simple decay model.
Origin story: why peptides need different clocks
Research on native GLP-1 showed that human plasma can convert it into a truncated form. That work helped distinguish persistence of the original peptide from detection of related material. A measurement must identify which molecular form it follows (Deacon et al., 1995).
Engineered peptides can behave differently. Semaglutide’s development program investigated structural changes intended to extend exposure. The question was not simply whether the molecule was still detectable, but how its design affected its pharmacological and kinetic profile (Lau et al., 2015).
The peptide basics guide introduces those structural differences. For half-life, keep identity attached to every time estimate. Native GLP-1, a truncated metabolite, and an engineered analog are not interchangeable analytes.
How peptide half-life works
In a simple first-order decline, the same fraction disappears during each equal time interval. If the half-life is two hours, half remains after two hours, one quarter after four, and one eighth after six. This is a mathematical model, not a universal measured peptide result.
The relationship is fraction remaining = 0.5 raised to the number of elapsed half-lives. After five half-lives, the model leaves 3.125% of the starting quantity. It does not say that the quantity has become exactly zero.
Actual concentration-time curves may include absorption, distribution, and a later decline. A reported terminal half-life refers to a defined portion of that curve. It should not automatically be applied to the entire time course from the first observation onward.
Also separate concentration from effect. A receptor response or downstream signal may have its own time course. A measured plasma half-life cannot, by itself, establish how long every biological endpoint changes.
Key evidence and a worked decay table
| Elapsed half-lives | Remaining fraction | Remaining percentage |
|---|---|---|
| 0 | 1 | 100% |
| 1 | 1/2 | 50% |
| 2 | 1/4 | 25% |
| 3 | 1/8 | 12.5% |
| 4 | 1/16 | 6.25% |
| 5 | 1/32 | 3.125% |
The table assumes one exponential decline, no new input, and a quantity that follows the model. It is useful for checking intuition, but its percentages should not be turned into an exposure schedule or a prediction for an uncharacterized preparation.
For actual examples, Wegovy’s prescribing information reports an elimination half-life of approximately one week for semaglutide. Zepbound’s information reports approximately five to six days for tirzepatide in the described populations. These are product- and study-context estimates, not shelf-life claims (FDA, 2026; Eli Lilly, accessed 2026).
The CJC-1295 study provides another caution about identity. Its multi-day half-life estimate concerns the long-acting construct used in that human study. It should not be assigned to another construct solely because a catalog name is similar (Teichman et al., 2006).
When building an evidence table, record analyte, species or population, formulation, route, sampling interval, and analysis method. Then attach the estimate. This prevents a result from one model from silently becoming a general property of the compound name.
Weak spots: what we don’t know
Half-life is an estimate, and the estimate depends on the observed data and method. Short sampling periods, a different assay, or measurement of total related material rather than intact peptide can change interpretation.
A longer half-life is also not automatically a better research property. A short-lived tool may be useful when the question requires a brief signal. A persistent tool may suit a different question. Neither number establishes selectivity or safety.
The solution shelf-life guide addresses storage separately. A peptide lasting days in circulation does not demonstrate that its stock solution remains unchanged for the same interval, or that a shorter biological half-life makes the dry material unstable.
As of November 5, 2026, approved semaglutide and tirzepatide medicines exist. Their approval and pharmacokinetic evidence do not transfer to supplier-branded research materials or establish equivalence between formulations (FDA, 2026; Eli Lilly, accessed 2026).
Handling half-life questions in the lab
Record the initial preparation concentration independently of any decay assumption. A nominal 5 mg sample recovered at a final volume of 2 mL gives 2.5 mg/mL, or 2,500 mcg/mL. A 0.10 mL analytical aliquot initially contains a nominal 250 mcg.
If a defined laboratory model truly follows one half-life over the observed interval, the modeled quantity would fall to half. That conditional calculation does not measure actual content and does not establish a stock’s storage behavior.
For a real stability or kinetic assessment, identify what the method detects and retain the time-stamped observations. Keep modeled estimates separate from measured values, particularly when the preparation or experimental system changes.
The reconstitution guide and calculator support concentration arithmetic. A calculator cannot infer a biological half-life from vial size, solvent volume, or appearance.
Peptide half-life FAQ
Does one half-life mean the peptide is gone?
No. In the simple decline model, half of the starting quantity remains.
Is biological half-life the same as vial shelf life?
No. They concern different systems and require different evidence.
Does a longer half-life prove a longer biological effect?
Not for every endpoint. Concentration and downstream responses need their own measurements.
What is Hero SM?
Hero SM is Hero Peptides’ semaglutide research material, listed in 5 mg and 10 mg vials. Its laboratory preparation is distinct from the approved medicine discussed in the pharmacokinetic example.
References
- Deacon CF, et al. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952-957. Source.
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. Source.
- U.S. Food and Drug Administration. Wegovy (semaglutide), prescribing information, section 12.3. 2026. Source.
- Eli Lilly and Company. Zepbound (tirzepatide), prescribing information, section 12.3. DailyMed, accessed November 5, 2026. Source.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.